Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Abstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Steven M. Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J. Ebert, John N. Calley, Isabella H. Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C. Ting, Jiangang Liu, Melinda D. Willard, Ruslan D. Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal, Hee Cheol Kim, Christoph Reinhard
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f456fa8deb9947ea89d5b6e8de43eb83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Ejemplares similares